Tc 99m ciprofloxacin

Drug Profile

Tc 99m ciprofloxacin

Alternative Names: INFECTON

Latest Information Update: 31 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BTG; St. Bartholomews Hospital
  • Developer DRAXIS Specialty Pharmaceuticals
  • Class Heavy metals; Radiopharmaceuticals
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Infections

Most Recent Events

  • 08 Jan 2008 Bristol-Myers Squibb Medical Imaging has been acquired by Avista Capital Partners, and is now known as Lantheus Medical Imaging
  • 29 Mar 2006 Enrolment has been completed in phase II studies in patients with soft tissue infections and in patients with osteomyelitis; enrolment is near completion in a phase II study in patients with diabetic foot ulcer, and is underway in patients with equivocal appendicitis
  • 17 Oct 2005 DRAXIS Specialty Pharmaceuticals has initiated enrolment a phase II trial with Tc 99m-labelled ciprofloxacin in patients with equivocal appendicitis in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top